Corgi | $108,000,000 | (Jan 9, 2026)
Corsera Health | $80,000,000 | (Jan 9, 2026)
Oasys | $4,600,000 | (Jan 9, 2026)
Certified by Founder
Lodge
LoQus23 Therapeutics Ltd
start up
United Kingdom
- Cambridge, Cambridgeshire
- 02/10/2024
- Series A
- $46,550,175
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.
- Industry Biotechnology Research
- Website https://loqus23.com/
- LinkedIn https://www.linkedin.com/company/loqus23-therapeutics-ltd/
Vizgen | $48,000,000 | (Jan 9, 2026)
Poplar Therapeutics | $50,000,000 | (Jan 9, 2026)
Carna Health | $8,000,000 | (Jan 9, 2026)
Valinor(US) | $54,000,000 | (Jan 9, 2026)
Alveus Therapeutics Inc | $160,000,000 | (Jan 9, 2026)
AgileRL | $7,500,000 | (Jan 9, 2026)
Soley Therapeutics | $200,000,000 | (Jan 9, 2026)
EpiBiologics | $107,000,000 | (Jan 9, 2026)
SpangleAI | $15,000,000 | (Jan 9, 2026)
Presto Phoenix, Inc. | $10,000,000 | (Jan 9, 2026)